Michael Atkins
MD
Deputy Director, Georgetown Lombardi Comprehensive Cancer Center
👥Biography 个人简介
Michael Atkins is a pioneering figure in RCC immunotherapy who contributed to early IL-2 based approaches and later to modern checkpoint inhibitor combinations. He was a co-investigator on CheckMate-214 establishing nivolumab plus ipilimumab for intermediate/poor-risk RCC and has explored predictive biomarkers for IO response. His work on sarcomatoid differentiation as a predictor of IO benefit has influenced patient selection strategies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Michael Atkins 的研究动态
Follow Michael Atkins's research updates
留下邮箱，当我们发布与 Michael Atkins（Georgetown University Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment